Verastem Oncology Appoints Matthew Ros as COO for Strategic Transition Ahead of Product Launch

Verastem Oncology Appoints New COO Amid Strategic Transition

Verastem Oncology, a biopharmaceutical company dedicated to developing treatments for cancers driven by the RAS/MAPK pathway, announces the appointment of Matthew E. Ros as its new chief operating officer. This strategic move comes as the company gears up for a pivotal mid-2025 product launch aimed at introducing a first-in-class treatment for low-grade serous ovarian cancer—a rare malignancy that currently has no approved therapies. Mr. Ros will report directly to Dan Paterson, the company’s president and CEO, and will be an integral part of the executive leadership team during this crucial transitional phase.

Matthew Ros brings with him over 35 years of extensive experience in the biopharmaceutical sector, particularly in driving operational excellence and fostering business transformations. His previous roles include CEO of FORE Biotherapeutics and key positions at prominent companies such as Epizyme, Sanofi-Genzyme, and ARIAD Pharmaceuticals. Notably, Ros's career began at Bristol-Myers Squibb in its Oncology division, where he played a significant role in launching major oncology products. His track record in building commercial organizations and securing FDA approvals positions him as a valuable asset for Verastem as it navigates the complexities of transitioning into a commercial-stage entity.

Dan Paterson, expressing optimism about Ros's appointment, underscores the importance of his expertise as the company prepares to expand its clinical programs for RAS/MAPK pathway-driven cancers, which often present limited treatment options. Mr. Ros has also served on the board of Cogent Biosciences and is actively involved in governance committees, further showcasing his commitment to advancing cancer treatment solutions. As Verastem Oncology prepares for its upcoming product launch, the company aims to leverage Ros's leadership to enhance its operational capabilities and ultimately improve patient outcomes in the realm of rare ovarian cancers.

In addition to Ros's appointment, Verastem remains focused on its mission to develop innovative therapies that address significant unmet medical needs in oncology. The company is poised to capitalize on its expertise and the evolving landscape of cancer treatment, striving to create impactful options for patients battling rare types of cancer. With Mr. Ros at the helm of operations, Verastem Oncology is set to embark on a new chapter aimed at significantly advancing the care landscape for women facing low-grade serous ovarian cancer.